More cash for gene therapy

Lysogene S.A.S. became the fifth gene therapy company this year to raise significant venture dollars. Investors in last week's series A round hope the company's lead product will provide better efficacy than enzyme replacement therapies for genetic diseases that have primary CNS involvement.

The lysosomal storage disorder company raised €16.5 million ($22.6 million) in a round co-led by existing investor Sofinnova Partners and new investors Bpifrance and Novo Seeds...